Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035

Report Format: PDF+Excel | Report ID: SR112025A8165

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Uterine Fibroids - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2019-2024) and Forecast (2025-2035)
4.4 Market Overview (2019-2024) and Forecast (2025-2035)
4.5 Competitive Intelligence

5 Uterine Fibroids - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Uterine Fibroids - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets

7.2.1 Epidemiology Scenario (2019-2024)
7.2.2 Epidemiology Forecast (2025-2035)
7.2.3 Epidemiology by Age (2019-2035)
7.2.4 Epidemiology by Gender (2019-2035)
7.2.5 Diagnosed Cases (2019-2035)
7.2.6 Patient Pool/Treated Cases (2019-2035)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2019-2024)
7.3.2 Epidemiology Forecast (2025-2035)
7.3.3 Epidemiology by Age (2019-2035)
7.3.4 Epidemiology by Gender (2019-2035)
7.3.5 Diagnosed Cases (2019-2035)
7.3.6 Patient Pool/Treated Cases (2019-2035)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2019-2024)
7.4.2 Epidemiology Forecast (2025-2035)
7.4.3 Epidemiology by Age (2019-2035)
7.4.4 Epidemiology by Gender (2019-2035)
7.4.5 Diagnosed Cases (2019-2035)
7.4.6 Patient Pool/Treated Cases (2019-2035)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2019-2024)
7.5.2 Epidemiology Forecast (2025-2035)
7.5.3 Epidemiology by Age (2019-2035)
7.5.4 Epidemiology by Gender (2019-2035)
7.5.5 Diagnosed Cases (2019-2035)
7.5.6 Patient Pool/Treated Cases (2019-2035)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2019-2024)
7.6.2 Epidemiology Forecast (2025-2035)
7.6.3 Epidemiology by Age (2019-2035)
7.6.4 Epidemiology by Gender (2019-2035)
7.6.5 Diagnosed Cases (2019-2035)
7.6.6 Patient Pool/Treated Cases (2019-2035)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2019-2024)
7.7.2 Epidemiology Forecast (2025-2035)
7.7.3 Epidemiology by Age (2019-2035)
7.7.4 Epidemiology by Gender (2019-2035)
7.7.5 Diagnosed Cases (2019-2035)
7.7.6 Patient Pool/Treated Cases (2019-2035)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2019-2024)
7.8.2 Epidemiology Forecast (2025-2035)
7.8.3 Epidemiology by Age (2019-2035)
7.8.4 Epidemiology by Gender (2019-2035)
7.8.5 Diagnosed Cases (2019-2035)
7.8.6 Patient Pool/Treated Cases (2019-2035)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2019-2024)
7.9.2 Epidemiology Forecast (2025-2035)
7.9.3 Epidemiology by Age (2019-2035)
7.9.4 Epidemiology by Gender (2019-2035)
7.9.5 Diagnosed Cases (2019-2035)
7.9.6 Patient Pool/Treated Cases (2019-2035)

8 Uterine Fibroids - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Uterine Fibroids - Unmet Needs

10 Uterine Fibroids - Key Endpoints of Treatment

11 Uterine Fibroids - Marketed Products
11.1 List of Uterine Fibroids Marketed Drugs Across the Top 7 Markets
11.1.1    Lupron Depot (Leuprolide Acetate for Depot Suspension) - AbbVie

11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2    Myfembree (Estradiol/Norethisterone acetate/Relugolix) - Sumitomo Pharma
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Oriahnn (Elagolix, Estradiol, and Norethindrone Acetate Capsules; Elagolix Capsules) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Yselty (Linzagolix choline) - Kissei Pharmaceutical/Theramex
11.1.4.1 Drug Overview    
11.1.4.2 Mechanism of Action    
11.1.4.3 Regulatory Status    
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 Uterine Fibroids - Pipeline Drugs
12.1 List of Uterine Fibroids Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name 

12.1.1.1 Drug Overview    
12.1.1.2 Mechanism of Action    
12.1.1.3 Clinical Trial Results    
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. Uterine Fibroids - Attribute Analysis of Key Marketed and Pipeline Drugs

14. Uterine Fibroids – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events

15 Uterine Fibroids - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets

15.2.1    Uterine Fibroids - Market Size
15.2.1.1 Market Size (2019-2024)
15.2.1.2 Market Forecast (2025-2035)
15.2.2    Uterine Fibroids - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2019-2024)
15.2.2.2 Market Forecast by Therapies (2025-2035)
15.3 Market Scenario - United States
15.3.1    Uterine Fibroids - Market Size
15.3.1.1 Market Size (2019-2024)
15.3.1.2 Market Forecast (2025-2035)
15.3.2    Uterine Fibroids - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2019-2024)
15.3.2.2 Market Forecast by Therapies (2025-2035)
15.3.3    Uterine Fibroids - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1    Uterine Fibroids - Market Size
15.4.1.1 Market Size (2019-2024)
15.4.1.2 Market Forecast (2025-2035)
15.4.2    Uterine Fibroids - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2019-2024)
15.4.2.2 Market Forecast by Therapies (2025-2035)
15.4.3    Uterine Fibroids - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1    Uterine Fibroids - Market Size
15.5.1.1 Market Size (2019-2024)
15.5.1.2 Market Forecast (2025-2035)
15.5.2    Uterine Fibroids - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2019-2024)
15.5.2.2 Market Forecast by Therapies (2025-2035)
15.5.3    Uterine Fibroids - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1    Uterine Fibroids - Market Size
15.6.1.1 Market Size (2019-2024)
15.6.1.2 Market Forecast (2025-2035)
15.6.2    Uterine Fibroids - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2019-2024)
15.6.2.2 Market Forecast by Therapies (2025-2035)
15.6.3    Uterine Fibroids - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1    Uterine Fibroids - Market Size
15.7.1.1 Market Size (2019-2024)
15.7.1.2 Market Forecast (2025-2035)
15.7.2    Uterine Fibroids - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2019-2024)
15.7.2.2 Market Forecast by Therapies (2025-2035)
15.7.3    Uterine Fibroids - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1    Uterine Fibroids - Market Size
15.8.1.1 Market Size (2019-2024)
15.8.1.2 Market Forecast (2025-2035)
15.8.2    Uterine Fibroids - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2019-2024)
15.8.2.2 Market Forecast by Therapies (2025-2035)
15.8.3    Uterine Fibroids - Access and Reimbursement Overview
15.9   Market Scenario - Japan
15.9.1    Uterine Fibroids  - Market Size
15.9.1.1 Market Size (2019-2024)
15.9.1.2 Market Forecast (2025-2035)
15.9.2    Uterine Fibroids - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2019-2024)
15.9.2.2 Market Forecast by Therapies (2025-2035)
15.9.3    Uterine Fibroids - Access and Reimbursement Overview

16 Uterine Fibroids - Recent Events and Inputs From Key Opinion Leaders

17 Uterine Fibroids Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats

18 Uterine Fibroids Market – Strategic Recommendations

19 Appendix

Uterine Fibroids Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials